Defense World
14 Mar 2026, 05:30 UTC · 27w ago
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings
Verdict
Headline leans bearish. We score CRVS −0.80.
Score confirms the headline.
- Headline says
Leans bearish
From its wording — no explicit rating
- Expected · CRVS
−0.80strongly bearish



